JAK1 Activates STAT3 Activity in Non-small-cell Lung Cancer Cells and IL-6 Neutralizing Antibodies Can Suppress JAK1-STAT3 Signaling

Overview

Journal Mol Cancer Ther

Date 2011 Jan 11

PMID 21216930

Citations 77

Authors

Lanxi Song

Bhupendra Rawal

Jeffrey A Nemeth

Eric B Haura

Affiliations

Soon will be listed here.

Abstract

Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.

Citing Articles

Equivocating and Deliberating on the Probability of COVID-19 Infection Serving as a Risk Factor for Lung Cancer and Common Molecular Pathways Serving as a Link.

Amara A, Trabelsi S, Hai A, Zaidi S, Siddiqui F, Alsaeed S Pathogens. 2025; 13(12.

PMID: 39770330 PMC: 11728627. DOI: 10.3390/pathogens13121070.

CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1.

Li M, Chen L, Yu F, Mei H, Ma X, Ding K Cell Death Discov. 2024; 10(1):389.

PMID: 39209829 PMC: 11362329. DOI: 10.1038/s41420-024-02162-5.

Mitochondria: a new intervention target for tumor invasion and metastasis.

Zhou Q, Cao T, Li F, Zhang M, Li X, Zhao H Mol Med. 2024; 30(1):129.

PMID: 39179991 PMC: 11344364. DOI: 10.1186/s10020-024-00899-4.

Interleukin-6 serves as a critical factor in various cancer progression and therapy.

Mohamed A, Ahmed A, Al Abdulmonem W, Olegovich Bokov D, Shafie A, Al-Hetty H Med Oncol. 2024; 41(7):182.

PMID: 38900329 DOI: 10.1007/s12032-024-02422-5.

An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1.

Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi I, Sun J, Politi K Br J Cancer. 2023; 128(9):1647-1664.

PMID: 36810913 PMC: 10133251. DOI: 10.1038/s41416-023-02196-z.

References

Kaplan D, Shankaran V, Dighe A, STOCKERT E, Aguet M, Old L . Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998; 95(13):7556-61. PMC: 22681. DOI: 10.1073/pnas.95.13.7556. View

Turkson J, Bowman T, Adnane J, Zhang Y, Djeu J, Sekharam M . Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol. 1999; 19(11):7519-28. PMC: 84756. DOI: 10.1128/MCB.19.11.7519. View

Trikha M, Corringham R, Klein B, Rossi J . Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9(13):4653-65. PMC: 2929399. View

Haura E, Muller A, Breitwieser F, Li J, Grebien F, Colinge J . Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res. 2010; 10(1):182-90. PMC: 3017669. DOI: 10.1021/pr100863f. View

Grivennikov S, Karin M . Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell. 2008; 13(1):7-9. DOI: 10.1016/j.ccr.2007.12.020. View

Yeh H, Lai W, Chen H, Liu H, Su W . Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene. 2006; 25(31):4300-9. DOI: 10.1038/sj.onc.1209464. View

Song L, Morris M, Bagui T, Lee F, Jove R, Haura E . Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006; 66(11):5542-8. DOI: 10.1158/0008-5472.CAN-05-4620. View

Haura E, Zheng Z, Song L, Cantor A, Bepler G . Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005; 11(23):8288-94. DOI: 10.1158/1078-0432.CCR-05-0827. View

Sun J, Blaskovich M, Jove R, Livingston S, Coppola D, Sebti S . Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 2005; 24(20):3236-45. DOI: 10.1038/sj.onc.1208470. View

10.

Wen Z, Darnell Jr J . Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res. 1997; 25(11):2062-7. PMC: 146718. DOI: 10.1093/nar/25.11.2062. View

11.

Nam S, Buettner R, Turkson J, Kim D, Cheng J, Muehlbeyer S . Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005; 102(17):5998-6003. PMC: 1087919. DOI: 10.1073/pnas.0409467102. View

12.

Yu H, Jove R . The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105. DOI: 10.1038/nrc1275. View

13.

Knoops L, Hornakova T, Royer Y, Constantinescu S, Renauld J . JAK kinases overexpression promotes in vitro cell transformation. Oncogene. 2007; 27(11):1511-9. DOI: 10.1038/sj.onc.1210800. View

14.

Guo A, Villen J, Kornhauser J, Lee K, Stokes M, Rikova K . Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008; 105(2):692-7. PMC: 2206598. DOI: 10.1073/pnas.0707270105. View

15.

Hedvat M, Huszar D, Herrmann A, Gozgit J, Schroeder A, Sheehy A . The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009; 16(6):487-97. PMC: 2812011. DOI: 10.1016/j.ccr.2009.10.015. View

16.

Wen Z, Zhong Z, Darnell Jr J . Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 1995; 82(2):241-50. DOI: 10.1016/0092-8674(95)90311-9. View

17.

Greulich H, Chen T, Feng W, Janne P, Alvarez J, Zappaterra M . Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005; 2(11):e313. PMC: 1240052. DOI: 10.1371/journal.pmed.0020313. View

18.

Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A . Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer. 2006; 55(3):349-55. DOI: 10.1016/j.lungcan.2006.11.003. View

19.

Yao Z, Fenoglio S, Gao D, Camiolo M, Stiles B, Lindsted T . TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010; 107(35):15535-40. PMC: 2932568. DOI: 10.1073/pnas.1009472107. View

20.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna A . High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005; 65(24):11478-85. DOI: 10.1158/0008-5472.CAN-05-1977. View